STI-6129

Phase 2

00%

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

10mo

ANROPhase 2$590M

STI-6129 Phase 2 Results Expected

STI-6129• Relapsed or Refractory Multiple Myeloma84

Dec 31Estimated

00%

Competitive Landscape

0 competitors in Relapsed or Refractory Multiple Myeloma

Drug Information

Target Indication

Relapsed or Refractory Multiple Myeloma

Clinical Trial

Last updated: 2/10/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

ANRO

Alto Neuroscience, Inc.

Related Pipeline

HCC

COVID-19

HER2-positive Breast Cancer

Malignant Neoplasms of Digestive Organs

Primary Hypercholesterolemia